Compared with sitagliptin 100 mg , canagliflozin 300 mg demonstrated superior diabetes-related quality measure attainment , including glycemic , BP , and weight-related quality measures ; there was no difference in LDL-C quality measure attainment between either dosage of canagliflozin and the 100-mg dosage of sitagliptin .